Tarsus posts $194.6 million in XDEMVY sales, advances four-drug pipeline
Tarsus reported third-quarter 2026 XDEMVY sales up about 64% year-over-year and outlined 2027-2029 milestones across TP-04, TP-05, IRX-101, and gildeuretinol.
SEC filing
3 stories
Tarsus reported third-quarter 2026 XDEMVY sales up about 64% year-over-year and outlined 2027-2029 milestones across TP-04, TP-05, IRX-101, and gildeuretinol.
SEC filing
Farrow, who serves as CFO and chief strategy officer of Tarsus Pharmaceuticals, joins Lisata's Audit Committee as the board expands to eight members.
SEC filing
The filing details the $270 million upfront cash payment, stock issuance, and up to $350 million in milestone payments for gildeuretinol.
SEC filing